Osteoprotegerin serum levels in rheumatoid arthritis

Journal fur Mineralstoffwechsel

Volumn 10, Issue 3, 2003, Pages 10-12

  Kolarz, Gernot ^a   Schodl C ^a   Skoumal, M ^a   Woloszczuk, W ^b   Wottawa, A ^c  

^a Rheuma Sonderkrankenanstalt SVAdGW   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c Institut fur Rheumatologie   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PEROXIDASE; PREDNISOLONE; RHEUMATOID FACTOR; STREPTAVIDIN;

ADULT; AGED; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CELL DIFFERENTIATION; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOASSAY; LARSEN SCORE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OSTEOCLAST; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; STEM CELL;

EID: 0141814711     PISSN: 10237763     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Sambrook PN. The skeleton in rheumatoid arthritis: Common mechanisms for bone erosion and osteoporosis? J Rheumatol 2000; 27: 2541-42.
2. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luethy R et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-19.
3. Itonaga I, Fujikawa Y, Sabokar A, Murray DW, Athanasou NA. Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. J Pathol 2000; 192: 97-104.
4. Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, Gay S. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthr Rheum 2000; 43: 2523-30.
5. Hofbauer LC, Heufelder AE, Erben RG. Osteoprotegerin, RANK, and RANK Ligand: the good, the bad, and the ugly in rheumatoid arthritis. J Rheumatol 2001; 28: 685-7.
6. Bolon B, Campagnuolo G, Hu YL, Duryeda D, Feige U. Arthritis patterns in rats with adjuvant-induced arthritis define distinct mechanisms of joint protection for IL-1 ra, sTNF RI, and OPG. Ann Rheum Dis 2000; 59 (Suppl. 1): 355.
7. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum 1988; 31: 315-24.
8. Fellinger K, Thumb N, Horak W, Grabner H. Computerdokumentation einer Rheumastation. Z Rheumafor 1973; 32: 257-71.
9. Prevoo M, van't Hof MA, Kuper H, van Leeuven MA, van de Putte LBA, van Riel PLCM. Modified disease activity scores that included twenty-eight joints counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthr Rheum 1995; 38: 44-8.
10. Larsen A, Pahle J. Radiograph evaluation of rheumatoid arthritis and related conditions by standard reference films. Act Radiol 1977; 18: 481-91.
11. Kudlacek S, Schneider B, Pietschmann P, Woloszczuk W, Willvonseder R. The effect of age on serum levels of osteoprotegerin. J Bone Miner Res 2001; 16 (Suppl 1): S195.
12. Srivastava SK, Weitzmann MN, Chaudhari LR, Namba N, Pacifici R. Estrogen decreases the responsiveness of osteoclast precursors to OPGL by down regulating OPGL induced JNK activity. J Bone Miner Res 1999; 14 (Suppl 1): 1178.
13. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999; 145: 527-38.
14. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1988; 188: 997-1001.
15. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315-23.
16. Horwood NJ, Elliot J, Martin TJ, Gillespie MT. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinol 1998; 139: 4743-6.
17. Kostenuik PJ, Morony S, Capparelli C, Lacey DL, Dunstan CR. Comparison of the inhibitory effects of osteoprotegerin and of APD on PTHrP-mediated hypercalcemia and bone remodelling. J Bone Miner Res 1999; 14 (Supp] 1): 1135.
18. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001; 276: 20659-72.
19. Kwon BS, Wang S, Udagawa N, Haridas V, Lee ZH, Kim KK et al. TR1, a new member of the tumor necrosis factor receptor family, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J 1998; 12: 845-54.
20. Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM. Osteoprotegerin and receptor activator of nuclear factor kappa B ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatol 2001; 40: 623-30.